Member Profile

Founded in 1982, Orient EuroPharma Co., Ltd (OEP) was officially listed in the Taipei Exchange in 2003. (Stock code: 4120) Business include pharmaceuticals, oncology drugs, dermo-cosmetics, infant & adult nutrition and healthcare products. OEP also established subsidiary companies: Orient PHARMA (Stock code: 4166), focusing on new drugs development and manufacture, conducted ability to integrate pharmaceutical ,R&D, clinical trial, manufacture and marketing. With the globalizing and growing market, OEP started to establish oversea subsidiaries since 1993 and strengthening OEP’s marketing and sales capability in the Asian Pacific region. Currently, overseas employees account for more than 40%.「Karihome」a new brand for infant nutrition market by OEP, which collaborated with New Zealand’s Dairy Goat Co-operatives (DGC) has successfully entered the Mainland China and Southeast Asia market. OEP is one of the few Taiwanese companies able to manage an international brand. The R&D and business strategy of OEP focus on the unique and niche market. To expand group business continuously, OEP developed technology platforms with patent to expand the competency of R&D and cooperate with globalized company to accelerate new product market with strategic alliance. OEP will uphold the core value「Through integrity, United we achieve and Be remarkable」to pursuit the sustainable development and accomplishment of a benchmarking enterprise in Asia-pacific.